ANTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
AN2 Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.12 |
52 Week High | US$22.22 |
52 Week Low | US$2.16 |
Beta | -0.051 |
1 Month Change | -10.17% |
3 Month Change | -35.95% |
1 Year Change | -60.45% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -86.23% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01Shareholder Returns
ANTX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -6.6% | 1.9% | 1.2% |
1Y | -60.4% | 16.7% | 27.7% |
Return vs Industry: ANTX underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: ANTX underperformed the US Market which returned 27.7% over the past year.
Price Volatility
ANTX volatility | |
---|---|
ANTX Average Weekly Movement | 8.8% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ANTX's share price has been volatile over the past 3 months.
Volatility Over Time: ANTX's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 41 | Eric Easom | www.an2therapeutics.com |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials.
AN2 Therapeutics, Inc. Fundamentals Summary
ANTX fundamental statistics | |
---|---|
Market cap | US$64.58m |
Earnings (TTM) | -US$66.03m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs ANTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ANTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$66.03m |
Earnings | -US$66.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.21 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ANTX perform over the long term?
See historical performance and comparison